
SNWV Stock Forecast & Price Target
SNWV Analyst Ratings
Bulls say
SANUWAVE Health Inc demonstrated strong financial performance in fiscal year 2024, achieving a remarkable 60% year-over-year revenue growth, totaling $32.6 million, attributed to increases in both system sales and consumables. The company also reported a significant improvement in AEBITDA, which increased by 28 points to 22%, reflecting enhanced operational efficiency and financial health. Although operating expenses rose to $6.4 million primarily due to non-cash stock-based compensation and NASDAQ fees, the overall growth metrics indicate a solid foundation for future expansion in the regenerative medicine market.
Bears say
SANUWAVE Health Inc. has demonstrated modest applicator usage decline in the first quarter compared to the fourth quarter, attributed to typical seasonal patient behavior following the annual insurance deductible reset in January, suggesting potential volatility in demand. Several financial challenges loom over the company, including margin compression, competitive pressures, diminished sales representative productivity, and potential manufacturing difficulties, all of which may hinder growth prospects. The dependence on maintaining relationships with group purchasing organizations further complicates the company's sales outlook, indicating a fragile market position that could adversely affect revenue generation.
This aggregate rating is based on analysts' research of SANUWAVE Health Inc and is not a guaranteed prediction by Public.com or investment advice.
SNWV Analyst Forecast & Price Prediction
Start investing in SNWV
Order type
Buy in
Order amount
Est. shares
0 shares